Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy

By LabMedica International staff writers
Posted on 28 Mar 2025

Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. More...

Due to the wide variation in symptoms between individuals, patients often struggle to obtain an accurate diagnosis. The standard method for diagnosing coeliac disease involves performing a biopsy of the duodenum (the first part of the small intestine). Pathologists then examine the sample under a microscope or on a computer to identify damage to the villi, which are tiny hair-like structures lining the small intestine. Interpreting these biopsies can be challenging, as the changes often appear subtle. Pathologists typically use the Marsh-Oberhuber scale to assess the severity of the condition, ranging from zero (normal villi, indicating a low likelihood of coeliac disease) to four (completely flattened villi, indicating severe disease). New research now shows that a machine learning algorithm was able to accurately determine, in 97 out of 100 cases, whether an individual had coeliac disease based on their biopsy.

This AI tool, developed by scientists at the University of Cambridge (Cambridge, UK), could expedite the diagnosis of coeliac disease, alleviate pressure on strained healthcare systems, and improve diagnoses in developing countries, where there is a significant shortage of pathologists. In research published in The New England Journal of Medicine AI, the Cambridge researchers presented their machine learning algorithm designed to classify biopsy image data. The algorithm was trained on a comprehensive dataset of over 4,000 images obtained from five hospitals, utilizing five different scanners from four different manufacturers. The team also tested their algorithm on an independent dataset of almost 650 images from an unseen source. When compared with the original diagnoses made by pathologists, the model correctly identified the presence or absence of coeliac disease in more than 97 cases out of 100.

The model demonstrated a sensitivity of over 95%, meaning it accurately identified more than 95 out of 100 individuals with coeliac disease. Additionally, it had a specificity of nearly 98%, meaning it correctly identified almost 98 out of 100 individuals without the disease. Previous research by the team has shown that even pathologists can have differing opinions. In one study, when asked to diagnose coeliac disease on a series of 100 slides, more than one in five cases led to disagreements among pathologists. In this new study, the researchers asked four pathologists to review 30 slides and found that a pathologist was just as likely to agree with the AI model as they were with another pathologist.

“This is the first time AI has been shown to diagnose as accurately as an experienced pathologist whether an individual has coeliac or not. Because we trained it on data sets generated under a number of different conditions, we know that it should be able to work in a wide range of settings, where biopsies are processed and imaged differently,” said Dr. Florian Jaeckle, from the Department of Pathology, and a Research Fellow at Hughes Hall, Cambridge. “This is an important step towards speeding up diagnoses and freeing up pathologists’ time to focus on more complex or urgent cases. Our next step is to test the algorithm in a much larger clinical sample, putting us in a position to share this device with the regulator, bringing us nearer to this tool being used in the NHS.”


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
Hemodynamic System Monitor
OptoMonitor
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.